Statera Biopharma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Blake Hawley
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2537 Research Boulevard Fort Collins CO United States of America 80526
- IPO Date
- Jul 28, 2021
- CIK
- 0001318641
- Website
- staterabiopharma.com
- Similar Companies
- Business
- Statera Biopharma, Inc. (STAB) develops novel immunotherapies that restore immune health and homeostasis through proprietary platforms leveraging pleiotropic natural analogs and advanced immunomodulating multi-component systems (AIMS); core products include STAT-201 for Crohn's disease, Entolimod for hematology indications including neutropenia and anemia, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19 acute and post-acute infections, with additional programs targeting fibromyalgia and multiple sclerosis; the company employs toll-like receptor (TLR) agonists such as TLR4, TLR9 antagonists, and TLR5 agonists including Entolimod and GP532 for radiation injury mitigation. Founded in 2003 as Cleveland BioLabs, Inc. in partnership with the Cleveland Clinic and reorganized through mergers including with Cytocom Inc. in 2021 to become Statera Biopharma, Inc., the company maintains headquarters in Fort Collins, Colorado. Statera Biopharma operates in the biopharmaceutical industry, focusing on immune modulation for autoimmune disorders, inflammatory conditions, infectious diseases, emerging viruses, and oncology; it targets patients requiring antigen-specific killer T-cell and antibody responses. In February 2025, Statera Biopharma licenses exclusive worldwide rights to its Phase III TLR5 agonist assets, including over sixty patents, know-how, and manufactured materials, to Tivic Health Systems, Inc., with select team members transitioning to support biopharmaceutical advancement.
BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice - BioGroup
BNP Paribas Primary New Issues: No STAB Notice - HOMEVI
BNP Paribas Primary New Issues: No STAB Notice - Lutech
BNP Paribas Primary New Issues: Post-STAB Notice - No Stab NEW IMMO HOLDING
CLARIANE BNP Paribas Primary New Issues: NO STAB Notice
AZELIS - BNP Paribas Primary New Issues: NO STAB Notice
BNP Paribas Primary New Issues: POST STAB NOTICE - NO STAB - EUTELSAT COMMUNICATIONS
BNP Paribas Primary New Issues: STAB Notice - NO STAB BETCLIC EVEREST GROUP
BNP Paribas Primary New Issues: POST-STAB Notice: No Stab TEREOS
Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast
BNP Paribas Primary New Issues: STAB Notice
Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
FORTUNE - BNP Paribas Primary New Issues: NO STAB Notice
BNP Paribas Primary New Issues: POST-STAB Notice: No Stab - PCC GLOBAL PLC
BNP Paribas Primary New Issues: POST-STAB Notice: No Stab - Gruppo San Donato S.P.A.
CROWN - BNP Paribas Primary New Issues: NO STAB Notice
BNP Paribas Primary New Issues: No STAB Sammontana
BNP Paribas Primary New Issues: STAB Notice - No Stab - Dometic Group AB
BNP Paribas Primary New Issues: STAB Notice - NO STAB REXEL S.A